Kobe, Japan, September 22-25, 2019

New Research to be Presented at the ET-16 Conference


The meeting will include diverse disciplines within molecular and cellular biology, physiology, development, reproductive medicine, pharmacology, pathophysiology, renal disease, cancer, inflammatory diseases, blood diseases, pain research, infectious disease,neurophysiology and neurology, stroke, vascular biology, coronary artery disease, peripheral vascular disease, pulmonary arterial hypertension, and particularly clinical studies using endothelin receptor antagonists. Attendees from different research communities will have the opportunity to explore areas of cross-disciplinary interest. We expect a broad representation from many disciplines and especially encourage students and young scientists to attend.  


Specifically, we expect
new results in the following areas to be presented at ET-16:

  • Novel ET signaling pathways
  • ET receptor heterodimerization
  • New models of hypertension and vascular injury involving the ET system
  • Role of ET in obesity, insulin resistance, diabetes and the metabolic syndrome
  • ET and the eye, including retinopathy and glaucoma
  • Involvement of ET in pain and narcotic tolerance
  • ET and cancer (including roles as survival or metastatic factor and assisted drug delivery)
  • Protective effects of ET blockade in cardiac fibrosis and cardiomyocyte survival
  • ET induction of fibrosis and epithelial-to-mesenchymal transition
  • ET in obesity and diabetes
  • Emerging concepts on the role of ET in regulating renal function and disease
  • ET in systemic sclerosis and autoimmune diseases
  • ET converting enzyme inhibitors in disease models
  • Clinical trials of ET receptor antagonists in pulmonary hypertension, cancer, renal disease, coronary artery disease, connective tissue diseases, and other disorders
  • ET in inflammation and immunomodulation, including rheumatic, transplant-related, and infectious causes